학술논문
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Document Type
article
Author
Source
Emerging Infectious Diseases, Vol 27, Iss 1, Pp 332-334 (2021)
Subject
Language
English
ISSN
1080-6040
1080-6059
1080-6059
Abstract
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.